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Abstract
Background: Variation of the gene coding for D2 receptors (DRD2) has been associated with risk for schizophrenia and with
working memory deficits. A functional intronic SNP (rs1076560) predicts relative expression of the two D2 receptors
isoforms, D2S (mainly pre-synaptic) and D2L (mainly post-synaptic). However, the effect of functional genetic variation of
DRD2 on striatal dopamine D2 signaling and on its correlation with prefrontal activity during working memory in humans is
not known.
Methods: Thirty-seven healthy subjects were genotyped for rs1076560 (G.T) and underwent SPECT with [
123I]IBZM (which
binds primarily to post-synaptic D2 receptors) and with [
123I]FP-CIT (which binds to pre-synaptic dopamine transporters,
whose activity and density is also regulated by pre-synaptic D2 receptors), as well as BOLD fMRI during N-Back working
memory.
Results: Subjects carrying the T allele (previously associated with reduced D2S expression) had striatal reductions of
[
123I]IBZM and of [
123I]FP-CIT binding. DRD2 genotype also differentially predicted the correlation between striatal dopamine
D2 signaling (as identified with factor analysis of the two radiotracers) and activity of the prefrontal cortex during working
memory as measured with BOLD fMRI, which was positive in GG subjects and negative in GT.
Conclusions: Our results demonstrate that this functional SNP within DRD2 predicts striatal binding of the two radiotracers
to dopamine transporters and D2 receptors as well as the correlation between striatal D2 signaling with prefrontal cortex
activity during performance of a working memory task. These data are consistent with the possibility that the balance of
excitatory/inhibitory modulation of striatal neurons may also affect striatal outputs in relationship with prefrontal activity
during working memory performance within the cortico-striatal-thalamic-cortical pathway.
Citation: Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, et al. (2010) Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity
during Working Memory Performance. PLoS ONE 5(2): e9348. doi:10.1371/journal.pone.0009348
Editor: Andre ´ Aleman, University of Groningen, Netherlands
Received September 15, 2009; Accepted January 29, 2010; Published February 22, 2010
Copyright:  2010 Bertolino et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Part of this work was supported by a National Institutes of Health (NIH) grant DA022199 (W.S.). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.bertolino@psichiat.uniba.it
Introduction
Susceptibility to schizophrenia is explained for the largest
fraction by genetic variation [1]. While the specific genes
conferring risk for schizophrenia are still undetermined, several
studies and meta-analyses point to the potential involvement of the
gene for dopamine D2 receptors (DRD2) [2,3]. Moreover, several
lines of evidence suggest involvement of the dopamine system and
of D2 signaling in the pathophysiology of schizophrenia [4–6].
Indeed, all antipsychotics available on the market block dopamine
D2 receptors (even though other receptors may also be involved).
Phenomenologically, schizophrenia is characterized by cognitive
deficits, in particular in the working memory domain [4]. Working
memory deficits in schizophrenia have been associated with
dysfunction of the prefrontal cortex [7,8] and of the dopamine
system [4,6]. Indeed, several authors have hypothesized that
altered working memory performance and related prefrontal activ-
ity can be part of a systems level pathophysiological mechanism
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9348also involving dopamine D2 receptors in the striatum [4,6]. The
key anatomical and molecular mechanisms regulating the rela-
tionship between DRD2 genetic risk, dopamine dysregulation
of D2 signaling, and working memory dysfunction remain
undetermined.
A large series of studies in animals indicates that prefrontal
neuronal activity during performance of working memory tasks is
regulated by dopamine [9]. In the prefrontal cortex both D1 and
D2 receptors are involved in working memory, with the latter
more specifically implicated in the response phase [9]. In this
regard, genetically modified mice lacking D2 receptors exhibit
behavioral working memory deficits and reduced activity of the
prefrontal cortex during treatment with D1 agonists [10].
Moreover, behavioral performance and prefrontal neuronal
activity during working memory (WM) performance are also
regulated by dopamine and D2 receptors in the striatum, a key
node within the cortico-striatal-thalamic-cortical circuit [11]. In
this regard, an experiment inducing developmental over-expres-
sion of striatal D2 receptors demonstrated specific working
memory deficits and altered prefrontal activity to D1 stimulation
[12]. These experiments in animals indicate that genetically
modified striatal D2 signaling has systems-level effects in dopamine
modulation of prefrontal cortical activity and related behaviors.
Data in humans have been consistent with these studies
demonstrating that infusion of D2 receptor agonists or antagonists
is respectively associated with relative improvement or deteriora-
tion of working memory performance [13] as well as of prefrontal
and striatal activity [14,15]. Other imaging studies in humans have
also demonstrated that striatal dopamine and D2 signaling are
correlated with prefrontal activity or behavioral performance
during different cognitive operations [16–18].
D2 receptors in the striatum are both pre- and post-synaptic and
affect the final output of the striatum to the thalamus, providing an
important regulation of prefrontal cortex stimulation [19]. At
present, however, it is unknown whether genetic determination of
pre- and post-synaptic striatal D2 signaling as modulated by
dopamine is a mechanism contributing to neuronal activity in
prefrontal cortex in humans. The D2 receptor gene (DRD2) codes
for two isoforms, D2S (short) and D2L (long). D2L receptors
mainly mediate post-synaptic signaling. D2S receptors mainly
serve as auto-receptors on pre-synaptic neurons [20], even though
they are also found on post-synaptic neurons [21]. Moreover, pre-
synaptic D2 receptors strongly contribute to physically regulate
density and activity of the dopamine transporter (DAT) [22–29].
An intronic DRD2 polymorphism (rs1076560,G .T) is associated
with mRNA splicing [30]. More specifically, the minor T allele is
associated with relatively reduced expression of D2S in prefrontal
cortex and striatum as well as with altered activity of the striato-
thalamic-prefrontal pathway during WM in healthy subjects [30]
and in schizophrenia [31]. However, the effect of this SNP on
prefrontal cortical activity may be also because of indirect effects
via the striatum [11]. The effects of this genetic variant on pre-
and post-synaptic signaling of dopamine in the striatum are not
known. In this study in healthy humans, we hypothesized that this
functional DRD2 variant, rs1076560, would be associated: with
differential binding of [
123I]IBZM measured with SPECT, which
reflects availability of post-synaptic D2 receptors [32]; with
differential binding of [
123I]FP-CIT measured with SPECT,
which reflects availability of pre-synaptic DAT [33]; and with
how a factor score of the two radiotracers identifying striatal D2
signaling would predict prefrontal activity measured with BOLD
fMRI during performance of a working memory task. Moreover,
in an effort to test the relative specificity of these associations,
subjects were also genotyped for COMT Val
158Met genotype
(rs4680). COMT is a key enzyme for dopamine catabolism in
prefrontal cortex but not in striatum [34,35] and this polymor-
phism alters activity of the enzyme in association with prefrontal
function [36].
Materials and Methods
Participants to [
123I]FP-CIT SPECT, [
123I]IBZM SPECT, and
BOLD fMRI Studies
Thirty-seven healthy subjects (16 males, mean age6SD
23.563.0 years) participated to [
123I]FP-CIT SPECT. Thirty-
two of these subjects underwent [
123I]IBZM SPECT and twenty-
eight also underwent Blood Oxygen Level Dependent (BOLD)
functional Magnetic Resonance Imaging (fMRI) during perfor-
mance of the N-Back task. Exclusion criteria included history of
significant drug or alcohol abuse (no active drug use in the past
year), head trauma with loss of consciousness, and any significant
medical condition. Parental socio-economical status (Hollingshead
Scale 40.4614.9), handedness (Edinburgh Inventory 0.7460.4),
and total IQ (WAIS-R, 108.1614.8) were measured. The present
study was approved by the local IRB. After complete description
of the study to the subjects, written informed consent was
obtained.
Genotype determination. DRD2 rs1076560 genotypes were
determined as in [29–31]. SNP rs1076560 was analyzed with
allele-specific PCR primers as described [37] or SNaPshot
(Applied Biosciences (ABI), Foster City CA) [38]. Consistent
with the distribution observed in earlier studies [38], no DRD2 TT
subjects were observed in this sample. COMT Val
158Met genotype
(rs4680) was determined as a restriction fragment length
polymorphism after PCR amplification and digestion with NlaIII
[39,40]. The allelic distribution of DRD2 and COMT was in Hardy
Weinberg equilibrium (DRD2 df 1, chi
2=2.1, p.0.1, COMT df 2,
chi
2=1.3, p.0.4).
Acquisition of SPECT data. Each subject was injected
intravenously with an average of 150 MBq (range 111–186 MBq)
of commercially available [
123I] FP CIT or [
123I]IBZM
radiotracer (GE Healthcare, Amersham, UK) [41–43]. These
two radiotracers bind to dopamine transporters [33] or D2
receptors [32], respectively. Potassium Iodide solution (Lugol) was
administered at least 3 hours before and 12 hours after
radiopharmaceutical injection to block thyroid uptake of free
radioactive iodide. Images were acquired 3–6 h after [
123I]FP-CIT
injection [44] or 1.5 hours after [
123I]IBZM injection [45]. A dual-
head gamma camera (Infinia, General Electric) equipped with
parallel-hole, low-energy high-resolution collimators was used.
SPECT data were acquired using the following parameters:
1286128 matrix, rotation of 360u, 60 view, 6u view angle, 45 s for
projection. Slice thickness was 3.68 mm, acquisition time was 22
minutes; total brain counts .1 million were achieved in all
examinations. Reconstruction was performed by filtered back-
projection with a Butterworth filter (cut-off frequency: 0.3 cycle/
cm, 10th order) to provide transaxial slices that were attenuation
corrected. Attenuation correction was performed according to
Chang’s method, (attenuation coefficient: 0.12 cm
21), after
manually drawing an ellipse around the head contour [46].
System spatial resolution (full width at half-maximum) at a radius
of rotation of 15.9 cm is 11 mm, as reported elsewhere [47]. For
analysis of striatal radiotracer uptake, slices were reoriented
parallel to the canthomeatal line.
Processing of SPECT data. The irreversible binding
characteristics and the stability of regional [
123I]FP-CIT and of
[
123I]IBZM uptake have been shown to allow estimation of the
specific-to-nondisplaceable equilibrium partition coefficient (V30),
DRD2 and Prefrontal Activity
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(Bmax) [48,49]. V30 can be calculated as indicated earlier [48,50].
Under equilibrium conditions between a compartment with
specific binding and a compartment representing nonspecifically
bound and free activity, V30 is proportional to Bmax given that
the dissociation constant and the volume of distribution of the
nonspecifically bound and free activity compartment (V2) are
relatively invariant. The occipital region was selected as the
background region because 1) the density of dopamine D2 and
DAT proteins is negligible compared with the striatum [51,52]; 2)
this region can be identified with greater reliability than the
cerebellum [53]; 3) in humans [
123I] IBZM activity in the occipital
region is equal to the nonspecific activity in the striatum [54].
Therefore, as in earlier studies [53,55,56], the occipital region was
used to model non-specifically bound and free activity
compartment. V30 can be calculated in all voxels with the
formula as in [50]:
counts per minute=voxel ðÞ VT
{ counts per minute=voxel ðÞ V2

counts per minute=voxel ðÞ V2
where VT represents specific binding, and V2 the nonspecifically
bound and the free activity compartment.
Image transformation, calculation of V30 and statistical analysis
was performed using SPM5 (Wellcome Department of Cognitive
Neurology, London, UK). V2 was calculated with a ROI of the
occipital lobe from the WFU Pickatlas (http://fmri.wfubmc.edu/
cms/software#PickAtlas) [57–59]. Since parametric images of
[
123I]FP-CIT and [
123I]IBZM V30 lack anatomical detail, an
indirect approach was employed for spatial normalization as
detailed in [50,60]. Briefly, the raw [
123I]FP-CIT and [
123I]IBZM
SPECT data of each subject were normalized on the SPECT
template in MNI (Montreal Neurological Institute) space [50] with
a 12-parameter affine transformation of the raw data onto the
template image followed by estimation of the nonlinear deforma-
tions between the applied images. A mean image of the previously
normalized raw data acquisitions was then computed and used as
a template image. For each individual SPECT acquisition, a
parametric V30 image was calculated. The raw data image was
transformed to the template image and the resulting transforma-
tion parameters were then applied to the corresponding subject’s
parametric V30 image. The spatially normalized parametric
images were convolved with a gaussian kernel (66666 mm) for
smoothing.
Statistical analyses of SPECT data. Two sample T tests
were used within SPM5 to evaluate potential differences between
genetic groups with a statistical threshold p,0.005, with further
correction for multiple comparisons within ROIs in putamen
obtained with the WFU_PickAtlas tool, p=0.05.
Binding of [
123I] FP-CIT and of [
123I] IBZM is associated with
protein density and affinity for the radiotracer as well as with the
relative concentration of endogenous dopamine occupying these
proteins [61,62]. Moreover, there is an extensive literature
detailing the interaction between dopamine transporters and D2
receptors [22–29,63]. Therefore, we hypothesized that the effects
of DRD2 genotype on striatal dopamine D2 signaling would be
additive and therefore identifiable with a measure reflecting the
shared and not the unique variance derived by the two radiotracer
binding measures. This index derived by factor analysis would
reflect individual dopamine D2 signaling and could be used for
correlation with fMRI activity. Therefore, we used a factor
analysis approach using a principal component analysis (PCA,
total variance used) as a reduction method [64] to combine
binding data from the two radiotracers into a single factor. We
performed a factor analysis using Principal component Analysis
(PCA) with STATISTICA (StatSoft, Tulsa, Oklahoma). [
123I]FP-
CIT and [
123I]IBZM V30 data were extracted in each subject from
a basal ganglia ROI, which included bilateral caudate and
putamen. ROIs were identified using the WFU PickAtlas software
(Functional MRI Laboratory at the Wake Forest University School
of Medicine, http://www.rad.wfubmc.edu/fmri) [57–59]. One
principal component (PC) that is a linear combination of the two
binding measures was estimated. This PC represents average
dopamine D2 signaling weighted by the variance of the binding
measures. For each subject we calculated a factor loading, which
indicates the weight of each subject bindings in the PC. PC
loadings were then used as predictors in random effects analyses to
identify potential relationships with the fMRI data in SPM (see
below).
v
2 is an effect size measure which estimates the proportion of
variance in a dependent measure accounted for by independent
categorical variables in the population from which the sample was
drawn. Thus, we used v
2 to measure the amount of variance
accounted for by DRD2 genotype. v
2 is given by the equation:
v2~ SSeffect { dfeffect ðÞ MSerror ðÞ ðÞ = MSerrorzSStotal ðÞ .
BOLD fMRI Data Acquisition and Processing
N-Back working memory paradigm. During fMRI, all
subjects completed a blocked paradigm of the N-Back task with a
2-Back working memory condition and a non-memory guided
control condition 0-Back [40,65]. This paradigm has been
extensively used to evaluate activity of prefrontal cortex. ‘‘N-
back’’ refers to how far back in the sequence of stimuli the subject
had to recall. The stimuli consisted of numbers (1–4) shown in
random sequence and displayed at the points of a diamond-shaped
box. There was a visually paced motor task which also served as a
non-memory guided control condition (0-Back) that simply
required subjects to identify the stimulus currently seen. In the
working memory condition, the task required recollection of a
stimulus seen two stimuli (2-Back) previously while continuing to
encode additionally incoming stimuli. Performance data were
recorded as the number of correct responses (accuracy) and as
reaction time.
BOLD fMRI acquisition parameters. Each subject was
scanned with a 3T MR scanner (GE) with a gradient-echo echo-
planar imaging (EPI) sequence using the following parameters:
20 contiguous axial slices, slice thickness=5 mm, echo time=
30 msec, repetition time=2000 msec; field of view 24 cm; matrix
64664, voxel size after normalization=3.75 mm isotropic
[40,66]. We used a simple block design in which each block
consisted of eight alternating 0-Back and 2-Back conditions (each
lasting 30 seconds), obtained in 4 min and 8 sec, 120 whole-brain
fMRI volumes. The first four scans of the time series were
acquired to allow the signal to reach a steady state and were not
included in the final analysis.
BOLD-fMRI image analysis. Preprocessing and statis-
tical analyses. Analysis of the fMRI data was completed using
statistical parametric mapping (SPM5; http://www.fil.ion.ucl.ac.
uk/spm). Images for each subject were realigned to the first
volume in the time series to correct for head motion (,2.5 mm of
translation, ,1.5u rotation), spatially normalized into a standard
stereotactic space (Montreal Neurological Institute, MNI,
template) using a 12 parameter affine model and smoothed to
minimize noise and residual differences in gyral anatomy with a
Gaussian filter, set at 10 mm full-width at half-maximum. Voxel-
DRD2 and Prefrontal Activity
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global mean. Each experimental condition was modeled with a
box car convolved with the hemodynamic response function
(HRF) at each voxel. Predetermined condition effects at each voxel
were calculated using a t-statistic, producing a statistical image for
the contrasts of 2-Back versus 0-Back (N-Back). All these individual
contrast images were then used in second-level random effects
models at the group level. ANOVA was used to evaluate the main
effects of working memory and of DRD2 genotype. Then, we
performed separate linear regression analyses for the two groups of
subjects (GG and GT) within SPM5. First, we entered the single
subject contrasts (2Back.0Back) with [
123I] IBZM or [
123I] FP-
CIT binding (from the anatomical ROIs differentiating the two
genotype groups) as predictors. These analyses do not exclude that
the biological effects of DRD2 genotype can result by additive
effects of genetic variants on both pre- and post- synaptic
compartments of D2 systems that would be captured by a D2
signaling factor (as detailed above). Thus, we also regressed
separately for the two genotype groups the single subject contrasts
(2Back.0Back) with factor scores from the factor analysis of the
SPECT data of each individual subject as predictors. All statistical
maps were thresholded at a level of p,0.005 uncorrected, with
further FWE small volume correction for multiple comparisons
with a=0.05 using a 10 mm radius sphere centered around
coordinates in prefrontal cortex published in previous studies of
working memory. These coordinates included: x 220, y 8, z 56
[65]; x 232, y 14, z 38 [67]; x 252, y 26, z 20 [68]; x 38, y 34, z
11 [69]. The studies used to perform small volume correction of
our data were selected based on the characteristics of the working
memory task that we have used [65,67,69], as well as on the aim of
the present study (i.e. to investigate the impact of variability in
dopamine genes on modulation of the functional activity of the
prefronto-striatal network, [68]). Because we did not have a priori
hypotheses regarding the activity of brain regions outside of the
prefrontal cortex, we used a statistical threshold of p=0.05,
corrected for multiple comparisons across all voxels, for these
whole-brain comparisons. For anatomical localization, statistical
maxima of activation were converted to conform to the standard
space of Talairach and Tournoux.
Polynomial regression to identify the correlation between
behavior, BOLD fMRI, and SPECT data. Because previous
evidence supports the hypothesis that the relationship between
working memory behavioral performance with dopamine signaling
and prefrontal activity is non-linear [9,70], we performed
polynomial regression to assess this relationship in our data. A
second order (quadratic) polynomial model was fitted to the data
separately inthetwogenotype groups: behavioral performanceat 2-
Back was the dependent variable; the dopamine D2 signaling factor
score (see above) and BOLD fMRI activity in prefrontal cortex
(from clusters correlated with the factor score itself) were the
independent variables. The F-statistic was used to compare the
goodness of fit of quadratic relative to linear model by comparing
the ratio of partitioned variances in the two genotype groups.
Results
Demographics and Working Memory Performance
Results
The two genotype groups did not differ for any of the
demographic measures (See also Supplemental Table S1, all
p.0.1) or for working memory behavioral performance (% correct
responses GG=83.4614.3, GT=88.1615.4; Reaction Time
GG=512.46219.1 msec, GT=562.06289.5; all p.0.2) thus
allowing us to examine the association of genotypes with brain
activity and dopamine signaling independent of behavioral
variation in this sample.
SPECT Results
Two-sample t test in SPM5 demonstrated that subjects
homozygous for the G allele had significantly greater specific
binding of [
123I]IBZM in right putamen (GG N=21, GT N=11,
Z=2.68; k=7; p=0.05, corrected; x 30, y 6, z 0, Figure 1)
compared with GT subjects. DRD2 genotype explained 20% of the
variance in [
123I]IBZM binding as indicated by v
2. Similarly, GG
subjects also had significantly greater specific binding of [
123I]FP-
CIT in left putamen (GG N=26, GT N=11, Z=3.1; k=13;
p=0.03, corrected; x 230, y 9, z 18, Figure 2). DRD2 genotype
explained 10% of [
123I] FP-CIT binding variance.
Figure 1. Association between DRD2 rs1076560 genotype and [
123I]IBZM binding. Coronal section of the effect of DRD2 rs1076560 genotype
(GG.GT) on [
123I]IBZM specific binding (V30) in right putamen (left) and relative scatterplot of individual data points from the cluster differentiating
the two groups (right).
doi:10.1371/journal.pone.0009348.g001
DRD2 and Prefrontal Activity
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123I]IBZM
and [
123I]FP-CIT basal ganglia ROIs load into one factor (GG
N=21, GT N=11, Factor loading for [
123I] FP-CIT=0.76,
factor loading for [
123I] IBZM=0.76, Eigenvalue 1.16, 58% Total
Variance) which presumably reflects dopamine D2 signaling.
In an effort to test the specificity of the association with DRD2,
SPECT data were also grouped and analyzed for COMT
Val
158Met genotype (rs4680). Because of the small number of
Met homozygous subjects, Met/Met and Met/Val subjects were
grouped together. Two sample t tests in SPM5 demonstrated no
significant association of COMT genotype with both [
123I]IBZM
(Met carriers N=19; Val/Val N=8) and [
123I]FP-CIT data (Met
carriers N=20; Val/Val N=10), even after lowering the statistical
threshold to p,0.01, uncorrected (data not shown).
fMRI Results
Effect of the 2-Back working memory task. As expected
from previous studies with the N-Back task [7,29,31,39,40,
65,71,72], ANOVA within SPM5 demonstrated that perfor-
mance of the 2-Back working memory condition was associated
with activity in a distributed network of brain regions including the
prefrontal cortex, the parietal cortex, and the striatum bilaterally.
Regions that also survived correction for multiple comparisons
include the left middle frontal gyrus (x 229, y 13, z 54, BA 6/8
and 9, Z=6.79, k=159, corrected p=0.000), the left inferior
frontal gyrus (x 251, y 15, z 19, BA 44/45, Z=5.55, k=83,
p=0.000) and the right middle frontal gyrus (x 40, y 40, z 15, BA
10/46, Z=5.42, k=66, p=0.000).
Effect of DRD2 genotype. Consistent with earlier studies
[29–31], ANOVA within SPM5 indicated that, despite similar
behavioral performance, GT subjects tend to have greater activity
in prefrontal cortex (x 33, y 21, z 45, middle frontal gyrus, BA 6,
Z=3.13, k=41, p=0.001; x 63, y 8, z 7, inferior frontal gyrus, BA
44, Z=3.36, k=16, p=0.0001) and anterior cingulate (x 10, y 16,
z 40, anterior cingulate, BA 32, Z=3.27, k=21, p=0.001)
compared with GG subjects. However, none of these results
survived correction for multiple comparisons.
Relationship between fMRI and SPECT data. Regression
analyses in SPM5 demonstrated a direct correlation between [
123I]
IBZM binding in right putamen with prefrontal cortex in GG
subjects (x 238, y 10, z 37, k=3, Z=3.1, p=0.02, corrected) and
a negative correlation in GT subjects (x 260, y 26, z 16, k=12,
Z=3.1, p=0.05, corrected). However, no correlation was found
in either group between [I
123] FP CIT binding and BOLD activity
during performance of the N-Back working memory task. Also,
regression analyses in SPM5 demonstrated a positive relationship
between the factor score obtained from SPECT data and BOLD
activity in prefrontal cortex in GG subjects (N=18; x 226, y 10, z
54, BA 6, Z=3.6, k=5, p=0.007 corrected; BA 9 x 234, y 16, z
30; Z=2.98, k=8, p=0.03, corrected, Figure 3)) and a negative
one in GT subjects (N=10; BA 46, Z=3.36, k=12, p=0.03,
corrected, x 259, y 30, z 12; BA 46 Z=2.77, k=5, p=0.09,
corrected, x 37, y 34, z 16, Figure 4; see also Supplemental Table
S2 for further results).
In GG subjects, there was a strong statistical trend for a
quadratic relationship between 2-Back percent correct responses
with the striatal dopamine D2 signaling factor score and prefrontal
activity during working memory as measured with fMRI
(R
2=0.45, F=2.67, df=4,13, p=0.07; F-statistic for quadratic
vs. linear model (4,13)=6.44, p=0.004; Univariate Results: factor
score
2 t=2.5, p=0.02; BOLD activity in BA9 x 234, y 16, z 30
2
t=1.9, p=0.07, Figures S1 and S2). In GT subjects, no such
relationship was evident (R
2=0.22, F=0.3, df=4,5, p=0.8).
Discussion
The results of the present study with multimodal imaging in
humans demonstrate that DRD2 rs1076560 genotype predicts
striatal [
123I]IBZM and [
123I]FP-CIT binding and the direction of
the correlation between a factor score reflecting striatal D2
signaling with prefrontal activity during performance of working
memory. More specifically, carriers of the T allele of rs1076560,
known to be associated with relatively reduced D2S, had reduced
[
123I]IBZM and [
123I]FP-CIT binding. Consistent with its
Figure 2. Association between DRD2 rs1076560 genotype and [
123I]FP-CIT binding. Coronal section of the effect of DRD2 rs1076560
genotype (GG.GT) on [
123I]FP-CIT specific binding (V30) in left putamen (left) and relative scatterplot of individual data points from the cluster
differentiating the two groups (right).
doi:10.1371/journal.pone.0009348.g002
DRD2 and Prefrontal Activity
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DRD2 genotype and with an earlier study which was published
while the present paper was being reviewed [73], COMT rs4680
genotype did not demonstrate any association with SPECT data.
Importantly, the present data also indicate that DRD2 genotype is
associated with qualitatively different relationships between
[
123I]IBZM binding and the striatal factor score with prefrontal
activity during working memory. GG subjects have a positive
correlation which is also weakly predictive of behavioral
performance, whereas in GT subjects the correlation is negative.
Earlier studies from our group had provided in vitro, post mortem and
in vivo evidence for the functionality of this SNP and for its
association with activity of the working memory network [30,31].
In the present study we provide evidence for a systems level
genetically determined mechanism correlating striatal D2 signal-
ing with alteration of prefrontal activity during working memory.
Figure 4. Correlation between BOLD fMRI activity in prefrontal cortex and the striatal dopamine D2 signaling factor in GT subjects.
3D rendering of the correlation between the striatal dopamine D2 signaling factor and BOLD fMRI activity during the 2-Back WM task in GT subjects
(left) with the relative scatterplot of the correlation in prefrontal cortex showing individual data points (right).
doi:10.1371/journal.pone.0009348.g004
Figure 3. Correlation between BOLD fMRI activity in prefrontal cortex and the striatal dopamine D2 signaling factor in GG subjects.
3D rendering of the correlation between the striatal dopamine D2 signaling factor and BOLD fMRI activity during the 2-Back WM task in GG subjects
(left) with the relative scatterplot of the correlation in prefrontal cortex showing individual data points (right).
doi:10.1371/journal.pone.0009348.g003
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[
123I]IBZM is believed to bind to post-synaptic D2 receptors
[17,32]. [
123I]IBZM binding can be modulated by endogenous
dopamine and by receptor density, affinity, and internalization
[53,74,75]. The rs1076560 G allele has been associated with greater
D2S expression, but not with total density of D2 receptors [30].
Thus, reduced [
123I]IBZM binding in GT subjects can reflect
reduced D2S receptors, which are also found post-synaptically [21].
Our [
123I]-IBZM results are also consistent with earlier studies
investigating the association between DRD2 polymorphisms and D2
binding with different radiotracers [76–78]. These polymorphisms
are in high linkage disequilibrium with rs1076560 and these earlier
studies have reported an average 30% reduction in D2 binding
based on genotype. Our data indicate that GT subjects have an
average 34% reduction in [
123I]-IBZM binding compared with GG
subjects. Resting state [
123I]FP-CIT measures pre-synaptic binding
to DATs [33]. Given the robust literature providing indication of
the physical and functional relationship between DATs and pre-
synapticD2receptors[28,29],reduced[
123I]FP-CITbindinginGT
subjects may be because of reduced pre-synaptic D2S. An
alternative interpretation of both SPECT datasets is also possible.
Because GT subjects have reduced pre-synaptic D2S which inhibits
dopamine release [19], reduced [
123I]IBZM and [
123I]FP-CIT
binding may be because of greater steady-state levels of dopamine
competing with the radiotracer. Consistent with these contentions
and with knowledge that the main factor contributing to a
relationship between pre-synaptic DATs and post-synaptic D2
receptors is dopamine itself, factor analysis of both SPECT datasets
identified a factor that may reflect dopamine D2 signaling (the
major element in common likely affecting binding of the two
radiotracers).
DRD2 rs1076560 genotype was also differentially associated
with the correlation between putative striatal dopamine D2
signaling (as identified with the factor score) and prefrontal activity
during working memory, which was positive in GG and negative
in GT subjects. A plausible cellular mechanism for these effects is
the differential contribution of dopamine D2S and D2L receptors
in modulation of glutamate and GABA transmission on striatal
output. Both D2 isoforms participate in pre-synaptic inhibition of
striatal GABA transmission, while D2S is preferentially involved in
modulation of glutamate release [21]. Therefore, modulation of
excitatory and inhibitory transmission in the striatum is tightly
linked to balance of the two isoforms [21]. In fact, GABA spiny
neurons, which account for the large majority of neuronal
populations in striatum, only fire action potentials when
depolarized by glutamate released by afferents from the cortex
[79]. Since DRD2 rs1076560 genotype alters the relative
expression of the two isoforms, our data are consistent with the
possibility that the balance of excitatory/inhibitory modulation of
striatal neurons may also affect striatal outputs and the relationship
with prefrontal activity during working memory.
Since the present study is in healthy subjects, no direct
conclusion can be drawn about schizophrenia. However, some
speculations as to the relevance of the present findings to
schizophrenia can be discussed. A long debated issue in the
pathophysiology of schizophrenia is whether subcortical dopamine
dysregulation is a primary phenomenon or rather it is associated
with prefrontal cortical dysfunction [4,80–82]. Indeed, heritability
of both these phenotypes has been demonstrated [83–87]. Several
studies and meta-analyses point to potential involvement of DRD2
in susceptibility to schizophrenia. Genome-wide linkage meta-
analyses have pointed to involvement of 11q [88]. Metanalyses of
case-control studies indicate SNPs rs1801028 (Cys
311Ser),
rs2283265, and rs6277 (C
957T) [2,3] as implicated in risk for
schizophrenia. Other recent family-based and case control studies
have also implicated these SNPs [89,90]. All these SNPs are linked
with rs1076560 in various degrees of LD. Given these earlier
studies in the literature and the present findings, it is possible to
speculate that risk for schizophrenia may involve the effects of
rs1076560 on striatal dopamine signaling and its relationship with
prefrontal activity. This speculation is also consistent with the
above cited animal studies indicating that developmentally
regulated over-expression of striatal D2 receptors is associated
with behavioral working memory deficits and with altered activity
of the prefrontal cortex [12].
A limitation of the present study needs to be addressed. The
time interval between the two SPECT scans was two weeks.
Although it would have been preferable that the SPECT and
fMRI scans were performed closely in time, this was not always the
case and the time interval between the two SPECT scans and the
fMRI scan was variable. On average, 25.663.6 months elapsed
between these scans. Earlier studies have demonstrated good
reproducibility for [
123I] IBZM (as good as 6.565.2 [91,92] and
for [
123I] FP CIT (5.5364.12%/0.89, [93]). As for fMRI,
reproducibility has been investigated in several studies using
different working memory paradigms. Studies have reported good
reproducibility of Dorsolateral Prefrontal cortex activation in
healthy subjects (Intra Class Correlation (ICC=0.81) coefficient
[94]). Similar results have also been reported by other investigators
[95,96]. These earlier studies suggest that it is less likely that the
time interval between scans has significantly influenced the results.
Moreover, it is important to underline that the relationships
identified in this study reflect known neurobiological pathways.
Also, there was no statistically significant difference between the
two genotype groups in time elapsed between SPECT scans and
fMRI (t=0.09, p=0.9) which may have unduly influenced the
differential correlations. Finally, SPECT and PET studies of DAT
and of D2 receptors have demonstrated between 3 and 7%
decrease of radiotracer binding per decade, especially after 40
years of age [97–101]. Since our healthy subjects are definitely
younger than 40 (mean age6SD 23.563.0), we believe physio-
logical dopamine signaling decline did not significantly affect our
analyses over the time interval of the study. Thus, we interpret
these findings as being consistent with stability of fMRI and
SPECT measures and as suggesting that they reflect neurobiolog-
ical mechanisms.
Another point that needs some discussion is that, at the chosen
statistical threshold corrected for multiple comparisons, we failed
to find a main effect of rs1076560 genotype on prefrontal activity
during performance of working memory in the present dataset. In
three earlier studies, we had already demonstrated association of
rs1076560 with prefrontal activity during performance of the N-
Back working memory task in healthy subjects with sample sizes as
large as N=142 [29–31]. In the present study, the sample
included 28 healthy subjects. Despite the smaller sample size, GT
subjects had greater activity in prefrontal cortex and anterior
cingulate before correction for multiple comparisons. Earlier
studies have demonstrated that larger sample sizes are generally
needed for imaging genetics studies using corrected statistical
thresholds [102]. Therefore, the present results suggest that the
lack of a statistically significant main effect of rs1076560 is likely
associated with the relatively small sample size of the present fMRI
study. Moreover, the main objective of the present fMRI data was
to evaluate statistically significant DRD2 modulation of the
relationship between striatal dopamine D2 signaling with
prefrontal activity during performance of working memory which
should not be affected by the corrected significance of the above
mentioned DRD2 effect.
DRD2 and Prefrontal Activity
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on modulation of the relationship between mesencephalic
dopamine and prefrontal cortex activity [103]. Indeed, the ventral
tegmental area in the mesencephalon may be implicated in these
mechanisms. Our data also provide evidence for a genetic
signature that affects striatal dopamine D2 receptor signaling
and its relationship with WM prefrontal activity, a mechanism
potentially involved in schizophrenia and other different brain
disorders [4].
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